Picture of Effector Therapeutics logo

EFTR — Effector Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

eFFECTOR Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

* eFFECTOR Therapeutics Inc  EFTR.OQ  reported a quarterly
adjusted loss of 23 cents​​ per share for the quarter ended in
September. The mean expectation of five analysts for the quarter
was for a loss of 21 cents per share.
    * Revenue rose 103% to $867.00 thousand from a year ago;
analysts
expected $642.20 thousand. 
    * eFFECTOR Therapeutics Inc's reported EPS for the quarter
was a
loss of 23 cents​.
    * The mean earnings estimate of analysts had fallen by
about 23.6%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * eFFECTOR Therapeutics Inc shares had fallen by 7.4% this
quarter and lost 93.6% so far this year.
    * The company reported a quarterly loss of $9.55 million.
    * Wall Street's median 12-month price target for eFFECTOR
Therapeutics Inc is $7.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
7 at 10:00 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.21          -0.23          Missed
 Jun. 30 2022      -0.16          -0.17          Missed
 Mar. 31 2022      -0.24          0.07           Beat
 Dec. 31 2021      -0.24          0.44           Beat

Recent news on Effector Therapeutics

See all news